Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of “Moderate Buy” from Analysts

Arcus Biosciences, Inc. (NYSE:RCUS) has received a consensus recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $35.10.

A number of equities analysts have recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a report on Monday, April 20th. Citigroup increased their target price on Arcus Biosciences from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Wedbush increased their target price on Arcus Biosciences from $37.00 to $41.00 and gave the stock an “outperform” rating in a report on Thursday, April 2nd. Leerink Partners set a $47.00 target price on Arcus Biosciences in a report on Monday, April 20th. Finally, Wells Fargo & Company set a $23.00 target price on Arcus Biosciences and gave the stock an “equal weight” rating in a report on Thursday, February 12th.

Arcus Biosciences Trading Down 0.2%

Arcus Biosciences stock opened at $23.16 on Monday. The business has a 50 day moving average price of $23.84 and a two-hundred day moving average price of $22.85. The company has a quick ratio of 4.04, a current ratio of 4.04 and a debt-to-equity ratio of 0.19. The stock has a market cap of $2.91 billion, a price-to-earnings ratio of -7.28 and a beta of 0.85. Arcus Biosciences has a 12 month low of $7.91 and a 12 month high of $28.72.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.10). Arcus Biosciences had a negative net margin of 156.36% and a negative return on equity of 68.97%. The firm had revenue of $17.00 million during the quarter, compared to analyst estimates of $29.49 million. During the same period last year, the company earned ($1.14) EPS. The company’s revenue was down 39.3% on a year-over-year basis. As a group, equities analysts forecast that Arcus Biosciences will post -3.61 EPS for the current year.

Insiders Place Their Bets

In related news, CAO Alexander Azoy sold 2,562 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $25.77, for a total transaction of $66,022.74. Following the completion of the sale, the chief accounting officer directly owned 39,581 shares of the company’s stock, valued at $1,020,002.37. This trade represents a 6.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Robert C. Goeltz II sold 7,763 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $25.63, for a total value of $198,965.69. Following the sale, the chief financial officer directly owned 84,161 shares of the company’s stock, valued at $2,157,046.43. This represents a 8.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 9.60% of the company’s stock.

Institutional Investors Weigh In On Arcus Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Hantz Financial Services Inc. increased its holdings in Arcus Biosciences by 121.9% during the 4th quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after purchasing an additional 881 shares in the last quarter. T. Rowe Price Investment Management Inc. acquired a new stake in Arcus Biosciences during the 4th quarter valued at $39,000. KBC Group NV acquired a new stake in shares of Arcus Biosciences in the 1st quarter valued at $50,000. SBI Securities Co. Ltd. increased its stake in shares of Arcus Biosciences by 13,547.6% in the 3rd quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock valued at $39,000 after buying an additional 2,845 shares during the period. Finally, GAMMA Investing LLC increased its stake in shares of Arcus Biosciences by 17.5% in the 4th quarter. GAMMA Investing LLC now owns 3,230 shares of the company’s stock valued at $77,000 after buying an additional 482 shares during the period. 92.89% of the stock is owned by institutional investors and hedge funds.

Key Arcus Biosciences News

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: LifescI Capital maintained an Outperform rating on Arcus Biosciences and set a $46 price target, signaling meaningful upside from current levels.
• Neutral Sentiment: The analyst’s updated forecasts for 2026-2030 remain broadly consistent across periods, suggesting no major near-term change in the long-term view on the company’s earnings trajectory.
• Negative Sentiment: Despite the upbeat rating, Lifesci Capital expects negative EPS in every period it covered, including losses of about ($4.15) in FY2026 and ($4.55) in FY2027, reinforcing concerns about profitability.
• Negative Sentiment: The estimates sit below zero even in later years, with projected losses of roughly ($4.52) in FY2028, ($4.56) in FY2029, and ($4.45) in FY2030, which may be keeping pressure on the stock.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.